Philippe JEAN-PIERRE
Professeur des universités en sciences de gestion
-
Adipocyte-specific Mlkl knockout mitigates obesity-induced metabolic dysfunction by enhancing mitochondrial functions
- Type de publi. : Article dans une revue
- Date de publi. : 06/10/2025
- Auteurs : Juliette TokgozogluValeria PistorioMirko MininiPierre-Antoine SoretVirginie SteunouJl DelaunayJulien CastelSerge LuquetIvan NemazanyyCarine BeaupèreLaetitia DinardTatiana LedentAurore L’honoréSara LemoinneChantal HoussetPhilippe LesnikVlad RatziuBruno FèveTounsia Aït‐slimaneAxelle CadoretNicolas ChignardJérémie Gautheron
Adipocyte-specific Mlkl knockout mitigates obesity-induced metabolic dysfunction by enhancing mitochondrial functions
- Type de publi. : Article dans une revue
- Date de publi. : 06/10/2025
- Auteurs : Juliette TokgozogluValeria PistorioMirko MininiPierre-Antoine SoretVirginie SteunouJl DelaunayJulien CastelSerge LuquetIvan NemazanyyCarine BeaupèreLaetitia DinardTatiana LedentAurore L’honoréSara LemoinneChantal HoussetPhilippe LesnikVlad RatziuBruno FèveTounsia Aït‐slimaneAxelle CadoretNicolas ChignardJérémie Gautheron
- Organismes : Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] European Reference Network on Hepatological Diseases [Hamburg, Germany] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Unité de Biologie Fonctionnelle et Adaptative Unité de Biologie Fonctionnelle et Adaptative Structure Fédérative de Recherche Necker Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Centre de Recherche Saint-Antoine Institut de Biologie Paris Seine Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche des Cordeliers Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière]
- Publié dans Cell Death and Disease le 22/10/2020
Résumé : Obesity is a global epidemic characterized by chronic low-grade inflammation and metabolic dysfunction, with adipose tissue playing a pivotal role in these processes. The mixed lineage kinase domain-like pseudokinase (MLKL) is a critical mediator of necroptosis but also exhibits noncanonical roles in metabolic regulation. This study aimed to investigate the adipocyte-specific functions of MLKL in obesity. Using adipocyte-specific Mlkl knockout ( Mlkl Adi-KO ) mice, we observed reduced susceptibility to high-fat diet (HFD)-induced obesity, enhanced glucose tolerance, and improved insulin sensitivity. Mlkl Adi-KO mice showed elevated energy expenditure independent of changes in food intake or locomotor activity, correlating with increased mitochondrial function and reduced lipid accumulation in white adipose tissue (WAT). Transcriptomic analyses of WAT revealed significant modulation of pathways linked to oxidative phosphorylation, inflammation, and lipid metabolism. Furthermore, metabolomic profiling highlighted reductions in TCA cycle intermediates, acylcarnitines, and pro-inflammatory amino acids in Mlkl Adi-KO mice under HFD conditions. These findings were accompanied by improved hepatic lipid profiles and decreased steatosis, underscoring systemic benefits of adipocyte-specific Mlkl deletion. Mechanistically, Mlkl deficiency altered adipocyte differentiation. These results position MLKL as a promising therapeutic target for obesity and related metabolic disorders, emphasizing the need for future studies using conditional knockout and overexpression models to explore its cell-specific and noncanonical functions in metabolic regulation.
Fichiers liés : Adipocyte-specific Mlkl knockout mitigates obesity-induced metabolic dysfunction by enhancing mitochondrial functions.pdf
Source -
Mostra A cerca paulina
- Type de publi. : Autre publication
- Date de publi. : 04/10/2025
- Auteurs : Sébastien QuenotCanarelli JulieLeandri YanPetru Couvidat-GherardiJean-Baptiste GeronimiDeborah CertoPhilippe SalortMarcandria PerautMadeleine FilippiPetru Couvidat-GherardiEugène GherardiJean-Baptiste GeronimiDeborah CertoPhilippe SalortChristophe LuziPierre-François MarchianiMarcandria PerautThibaut DauphinMichel Vergé-FranceschiJean-Guy TalamoniMadeleine Filippi
Mostra A cerca paulina
- Type de publi. : Autre publication
- Date de publi. : 04/10/2025
- Auteurs : Sébastien QuenotCanarelli JulieLeandri YanPetru Couvidat-GherardiJean-Baptiste GeronimiDeborah CertoPhilippe SalortMarcandria PerautMadeleine FilippiPetru Couvidat-GherardiEugène GherardiJean-Baptiste GeronimiDeborah CertoPhilippe SalortChristophe LuziPierre-François MarchianiMarcandria PerautThibaut DauphinMichel Vergé-FranceschiJean-Guy TalamoniMadeleine Filippi
- Organismes : Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA)
Source -
A Cerca paulina
- Type de publi. : Ouvrage (y compris édition critique et traduction)
- Date de publi. : 02/10/2025
- Auteurs : Sébastien QuenotCouvidat-Gherardi PetruGherardi EugèneCanarelli JulieLeandri YanGeronimi Jean-BaptisteCerto DeborahSalort PhilippeLuzi ChristopheMarchiani Pierre-FrançoisPeraut MarcandriaDauphin ThibautVergé-Franceschi MichelTalamoni Jean-GuyFilippi Madeleine
A Cerca paulina
- Type de publi. : Ouvrage (y compris édition critique et traduction)
- Date de publi. : 02/10/2025
- Auteurs : Sébastien QuenotCouvidat-Gherardi PetruGherardi EugèneCanarelli JulieLeandri YanGeronimi Jean-BaptisteCerto DeborahSalort PhilippeLuzi ChristopheMarchiani Pierre-FrançoisPeraut MarcandriaDauphin ThibautVergé-Franceschi MichelTalamoni Jean-GuyFilippi Madeleine
- Organismes : Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Centre National de la Recherche Scientifique Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli] Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA) Institut de Recherche Montesquieu Université de Tours Laboratoire « Lieux, Identités, eSpaces, Activités » (UMR CNRS 6240 LISA)
Source -
Spatio-temporal dynamics of L-band zeroth-order vegetation scattering albedo from SMAP observations in tropical forests
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Yuqing LiuXiaojun LiPhilippe CiaisFrédéric FrappartXiangzhuo LiuEric G. CosioYi ZhengZanpin XingHuan WangLei FanMario Julian ChaubellWigneron J.-P.
Spatio-temporal dynamics of L-band zeroth-order vegetation scattering albedo from SMAP observations in tropical forests
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Yuqing LiuXiaojun LiPhilippe CiaisFrédéric FrappartXiangzhuo LiuEric G. CosioYi ZhengZanpin XingHuan WangLei FanMario Julian ChaubellWigneron J.-P.
- Organismes : Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Contrôles des cycles biogéochimiques terrestres Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère National Sun Yat-sen University Interactions Sol Plante Atmosphère Peking University [Beijing] Southwest University [Chongqing] Jet Propulsion Laboratory Interactions Sol Plante Atmosphère
- Publié dans Remote Sensing of Environment le 28/10/2020
Résumé : The effective scattering albedo (omega) is a key parameter in the zero-order radiative transfer equation (known as the tau-omega model) for passive microwave retrieval of soil moisture (SM) and vegetation optical depth (VOD), quantifying the scattering energy loss as microwave radiation passes through the vegetation canopy. The scattering effects of vegetation are influenced by time-dependent factors such as plant geometry, vegetation water content, and canopy structure, suggesting that omega may vary over time. However, in the current tau-omega model-based retrieval algorithms used by orbiting L-band sensors, namely the Soil Moisture and Ocean Salinity (SMOS) and the Soil Moisture Active Passive (SMAP), omega is generally assumed to be time-invariant and assigned a fixed value according to land cover types. In this study, we aim to analyze and understand the spatio-temporal dynamics of omega, its relationship with vegetation water stress and the driving factors behind microwave scattering characteristics over tropical forests. By assuming a vegetation transmittance of zero for rigorously selected dense forest areas in the tropics, we calculated omega from the SMAP L-band radiometer observations during 2018-2023. Regarding the spatial distribution of omega, we observed distinct spatial dynamics within the same land cover type. The lowest omega values were typically found in the northeastern Amazon. Additionally, omega exhibited clear temporal dynamics, displaying a unimodal pattern in the Amazon and a bimodal pattern in the Congo. Clear polarization dependence of omega was observed, with values consistently higher at Horizontal (H-) polarization compared to Vertical (V-) polarization. Despite this, the seasonal patterns of omega are similar at both H- and V-polarizations. The seasonal variation of omega was found to be asynchronous with soil water availability indicated by root zone soil moisture (RZSM) across different regions. The shortest time lags (0-30 days) between omega and RZSM were observed in the densely vegetated northeastern Amazon, while the longest occurred in the northeastern Congo. A machinelearning based interpretation of the spatial variability of omega and time lag indicates that the values of omega are strongly and inversely related to canopy height, while the time lag is mainly associated with precipitation and soil water content. Our results deepen the understanding of the spatio-temporal dynamics of omega and could contribute to the improvement of SM and VOD retrieval algorithms, thereby enhancing the utility of these variables as indicators for monitoring vegetation carbon dynamics and phenology in dense tropical forests.
Source -
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Claire ChatorMarion ChevrierJean-Sébastien FrenelFrédéric GuyonRenaud SabatierChristophe PomelThibault de la Motte RougePatricia PautierLaurence GladieffPhilippe FollanaPierre-Emmanuel ColomboThierry PetitCécile GuillemetFrédéric MarchalFabrice NarducciJean-David FumetManuel RodriguesLise BosquetRoman RouzierIsabelle Ray-Coquard
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Claire ChatorMarion ChevrierJean-Sébastien FrenelFrédéric GuyonRenaud SabatierChristophe PomelThibault de la Motte RougePatricia PautierLaurence GladieffPhilippe FollanaPierre-Emmanuel ColomboThierry PetitCécile GuillemetFrédéric MarchalFabrice NarducciJean-David FumetManuel RodriguesLise BosquetRoman RouzierIsabelle Ray-Coquard
- Organismes : Centre Léon Bérard [Lyon] Institut Curie [Paris] Institut de Cancérologie de l'Ouest [Angers/Nantes] Institut Bergonié [Bordeaux] Institut Paoli-Calmettes Centre Jean Perrin [Clermont-Ferrand] Imagerie Moléculaire et Stratégies Théranostiques CRLCC Eugène Marquis Institut Gustave Roussy Institut Universitaire du Cancer de Toulouse - Oncopole Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle Institut de Cancérologie de Strasbourg Europe Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] Centre de Recherche en Automatique de Nancy Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Service d'oncogénétique [Centre georges-François Leclerc] Institut Curie [Paris] UNICANCER [Paris] Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon]
- Publié dans Gynecologic Oncology le 25/10/2020
Résumé : Objective: Approximately 70 % of patients with epithelial ovarian cancer (EOC) will relapse. Beyond the platinum-free interval (PFI), predictive factors for efficacy of subsequent therapies are poorly understood. We evaluated the impact of the PFI on progression-free survival (PFS), overall survival (OS) and the role of therapies used at relapse. Methods: This retrospective study using the French ESME Ovarian Database included patients with first relapse of EOC after front-line platinum-based chemotherapy (PBCT). The impact of prognostic factors on survival was analyzed using multivariate Cox regression, with results expressed as hazard ratios, adjusted for patient and tumor characteristics, including a subgroup analysis of high-grade serous cancer. Results: 5558 patients, treated between 2010 and 2019 were included (median age 65 IQR 57-71). Median second- and third line PFS and OS were proportionally higher with PFI prolongation. Other factors influencing PFS and OS were BRCA mutation, FIGO stage, chemotherapy and maintenance regimens, and PS. PBCT was more effective than single-agent chemotherapy, even with a PFI < 6 months (PFSn2: adjusted HR = 0.48 95 %IC [0.43;0.53], OSn2: HR = 0.51 95 %IC [0.46;0.57]). Use of PARP inhibitors (PARPi) in second line seems to reduce outcomes in the third line. Findings were consistent in the HGSC subgroup. Conclusion: PFI remains an important prognostic factor but should no longer be the sole consideration for treatment selection at relapse in EOC, particularly in HGSC. The potential impact of prior PARPi maintenance on subsequent PBCT warrants investigation in prospective trials.
Source -
Long-Term Quality of Life and Functional Outcome Analysis of Surgically Managed Central Neurocytoma Patients: Results of a Multicenter Study
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Charles-Henry MallereauGuillaume VirbelJohan PalludFrançois SeveracAmélie DarlixCaroline MolleviEtienne LefevreMatthieu PeyrePaul RoblotJulien NicolauLubin KlotzYves SahlerTuan Le VanInsafe MezjanAnis ChouchaMaxime RivollierChristophe BoulloudPhilippe PageThiébaud PicartThomas MetayerAmandine GavottoAurore SellierJohanna ClaquinJean-Michel LeméeNoor HamdanJulien TodeschiHélène CebulaSalvatore ChibbaroMathias BilgerFabienne BauchetSonia ZouaouiBenoit LhermitteDominique Figarella‑brangerValérie RigauBrigitte TrétarreFrançois ProustGeorges NoelLuc Bauchet
Long-Term Quality of Life and Functional Outcome Analysis of Surgically Managed Central Neurocytoma Patients: Results of a Multicenter Study
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Charles-Henry MallereauGuillaume VirbelJohan PalludFrançois SeveracAmélie DarlixCaroline MolleviEtienne LefevreMatthieu PeyrePaul RoblotJulien NicolauLubin KlotzYves SahlerTuan Le VanInsafe MezjanAnis ChouchaMaxime RivollierChristophe BoulloudPhilippe PageThiébaud PicartThomas MetayerAmandine GavottoAurore SellierJohanna ClaquinJean-Michel LeméeNoor HamdanJulien TodeschiHélène CebulaSalvatore ChibbaroMathias BilgerFabienne BauchetSonia ZouaouiBenoit LhermitteDominique Figarella‑brangerValérie RigauBrigitte TrétarreFrançois ProustGeorges NoelLuc Bauchet
- Organismes : Hôpital de Hautepierre [Strasbourg] Institut de Cancérologie de Strasbourg Europe Institut de psychiatrie et neurosciences de Paris Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Centre Hospitalier Universitaire [Strasbourg] Institut de Génomique Fonctionnelle Institut régional de Cancérologie de Montpellier Université de Montpellier CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre hospitalier territorial Gaston-Bourret [Dumbea] Service Neurochirurgie [CHU Toulouse] Service Neurochirurgie [CHU Toulouse] Service de neurochirurgie [Rennes] = Neurosurgery [Rennes] Service de neurochirurgie [CHU Dijon] Service de Neurochirurgie [CHRU Nancy] Service de neurochirurgie [CHU Marseille] Hôpital universitaire Robert Debré [Reims] Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Service de Neurochirurgie [CHU de Poitiers] Centre de Recherche en Cancérologie de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service de Neurochirurgie [CHU Caen] Département de Neurochirurgie [Hôpital Pasteur de Nice] Hopital d'instruction des armées Sainte-Anne [Toulon] Centre Hospitalier Universitaire de La Réunion Département de neurochirurgie [Angers] Service de Neurochirurgie [CHRU Besançon] Hôpital de Hautepierre [Strasbourg] Hôpital de Hautepierre [Strasbourg] Hôpital de Hautepierre [Strasbourg] University Hospital of Siena Centre Hospitalier Universitaire [Strasbourg] Registre des Tumeurs de l'Hérault Institut régional de Cancérologie de Montpellier Neurochirurgie [Hôpital Gui de Chauliac] Centre Hospitalier Universitaire [Strasbourg] Institut de neurophysiopathologie Hôpital de la Timone [CHU - APHM] Hôpital Gui de Chauliac [CHU Montpellier] Institut de Génomique Fonctionnelle Registre des Tumeurs de l'Hérault Institut régional de Cancérologie de Montpellier Hôpital de Hautepierre [Strasbourg] Institut de Cancérologie de Strasbourg Europe Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle
- Publié dans Neurosurgery le 01/11/2020
Résumé : Background and objectives: Central neurocytoma (CN) is a rare grade 2 intraventricular tumor according to the 2021 World Health Organization classification. Surgical resection is the recommended management. This study aimed at assessing patients' health-related quality of life (HRQoL) and functional outcomes at long-term postoperative follow-up. Methods: A multicenter retrospective study was conducted in 42 French neurosurgical centers. CN patients treated by surgical resection between 2006 and 2015 were included. We collected clinical, imaging, and surgical data. HRQoL was assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (QLQ-C30) and its brain cancer-specific module (QLQ-BN20). Functional outcomes were evaluated by professional integration, return to driving, epileptic disease, and Karnofsky Performance Status (KPS) score. Results: Among 65 long-term postsurgery patients (median 11 years of follow-up), self-reported overall HRQoL score was 75.5 ± 18.4. Favorable cognitive, asthenia, and emotional scores were observed in 36.9%, 84.6%, and 72.3% of cases, respectively. Various degrees of professional integration were observed in 63.1%, driving resumption in 72.3%, and favorable KPS (>70) in 78.4% of cases; 33.8% of patients experienced daily epileptic treatment. The absence of acute postoperative hydrocephalus was significantly related with favorable functional outcomes for asthenia, professional integration, and global KPS. Conclusion: CN patients treated by surgical resection showed generally high long-term HRQoL scores. However, cognitive outcomes remain severely affected with only one-third of patients achieving favorable results. Management of acute postoperative hydrocephalus represents a crucial factor for patients' functional prognosis and warrants clinicians' attention.
Source -
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Heloise BourienXavier AdhouteBoris Campillo-GimenezMohamed BouattourEric AssenatPierre NahonSimon LaunayFrédéric ObertiAntonio SavianoThomas DecaensPhilippe MerleAlexandre HarléThierry LecomteDavid TernantLaure MonardVeronica PezzellaJean-Frédéric BlancJulien Edeline
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Heloise BourienXavier AdhouteBoris Campillo-GimenezMohamed BouattourEric AssenatPierre NahonSimon LaunayFrédéric ObertiAntonio SavianoThomas DecaensPhilippe MerleAlexandre HarléThierry LecomteDavid TernantLaure MonardVeronica PezzellaJean-Frédéric BlancJulien Edeline
- Organismes : CRLCC Eugène Marquis Hôpital Saint-Joseph [Marseille] CRLCC Eugène Marquis Service d’Anatomie Pathologique [CHU Beaujon] CHU Montpellier = Montpellier University Hospital Hôpital Avicenne [AP-HP] Institut Paoli-Calmettes Centre Hospitalier Universitaire d'Angers Laboratoire de Génétique Moléculaire [CHRU Strasbourg] Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Hôpital de la Croix-Rousse [CHU - HCL] Centre de Recherche en Automatique de Nancy Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours R&D Unicancer [Paris] Hôpital Haut-Lévêque [CHU Bordeaux] Hôpital Haut-Lévêque [CHU Bordeaux] CRLCC Eugène Marquis
- Publié dans Digestive and Liver Disease le 01/11/2020
Résumé : Background Hepatocellular carcinoma (HCC) frequently develops in underlying cirrhosis. Liver dysfunction impacts survival and may influence treatment results. About a quarter of patients with advanced HCC present with Child-Pugh B liver functions. All recent phase 3 trials validating standard of care limited inclusion to patients with Child-Pugh A liver function. Results of immunotherapy is less described in patients with altered liver function. We previously showed that the ALBI grade might be able to better select patients with Child-Pugh B liver functions who could benefit from sorafenib. Single-agent anti-PD-(L)1 antibodies might have a more favorable safety profile than standard of care combinations. Methods We thus launched a study, the HESTIA trial, testing tislelizumab, an anti-PD-1 antibody that was demonstrated as non-inferior to sorafenib as first-line treatment, in the population of patients with advanced HCC, Child-Pugh B and ALBI grade 1 or 2 liver function. Results In this article, we present the design of the study and first safety results. This is a single-arm phase 2 study. Fifty patients will be included. The primary endpoint is objective response rate. The first safety analysis showed no signal of increased toxicity of the drugs. However, this population is at high risk for liver-related adverse events. Conclusion The study is currently pursuing accrual.
Source -
Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Jean-Yves BlayMaud ToulmondeThibaud ValentinNelly FirminSarah WatsonFlorence DuffaudEmmanuelle BompasMaria RiosMikael RoparsPhilippe AnractArmelle DufresneJustine GantzerLouis-Romée Le NailEsma SaadaAlice HervieuFrançois BertucciPascale Dubray-LongerasVincent CrennChristophe PerrinPauline SoibinetBenjamin VerretAntoine ItalianoGauthier DecanterGwenael FerronSebastien CarrereSylvie BonvalotMehdi BrahmiClémence HénonMariella Spalato-CerusoLoic LebellecAnne DucassouJulien Colard-ThomasSophie Piperno-NeumannJean-Camille MatteiFrancois GouinMathieu FaronThomas RyckewaertPierre MeeusCharles HonoréFrançois Le LoarerJean-Michel CoindreCarine NgoAlexandra MeurgeyMarie KaranianClaire Chemin-AiriauFrançoise DucimetiereMagali MorelleNicolas PenelAxel Le Cesne
Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Jean-Yves BlayMaud ToulmondeThibaud ValentinNelly FirminSarah WatsonFlorence DuffaudEmmanuelle BompasMaria RiosMikael RoparsPhilippe AnractArmelle DufresneJustine GantzerLouis-Romée Le NailEsma SaadaAlice HervieuFrançois BertucciPascale Dubray-LongerasVincent CrennChristophe PerrinPauline SoibinetBenjamin VerretAntoine ItalianoGauthier DecanterGwenael FerronSebastien CarrereSylvie BonvalotMehdi BrahmiClémence HénonMariella Spalato-CerusoLoic LebellecAnne DucassouJulien Colard-ThomasSophie Piperno-NeumannJean-Camille MatteiFrancois GouinMathieu FaronThomas RyckewaertPierre MeeusCharles HonoréFrançois Le LoarerJean-Michel CoindreCarine NgoAlexandra MeurgeyMarie KaranianClaire Chemin-AiriauFrançoise DucimetiereMagali MorelleNicolas PenelAxel Le Cesne
- Organismes : Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Institut Bergonié [Bordeaux] Oncopole Claudius Regaud Service Hématologie - IUCT-Oncopole [CHU Toulouse] Institut de Recherche en Cancérologie de Montpellier Institut régional de Cancérologie de Montpellier Institut Curie [Paris] Hôpital de la Timone [CHU - APHM] CRLCC René Gauducheau Centre Alexis Vautrin Hôpital Sud [CHU Rennes] Hôpital Cochin [AP-HP] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Institut de Cancérologie de Strasbourg Europe Centre Hospitalier Universitaire [Strasbourg] CHU Trousseau [Tours] Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] Centre de Recherche en Cancérologie de Marseille Institut Paoli-Calmettes Centre Jean Perrin [Clermont-Ferrand] Service des Urgences [CHU Nantes] Laboratoire Mécanismes d'Accidents Université Gustave Eiffel Institut Jean Godinot [Reims] Institut Gustave Roussy Institut Bergonié [Bordeaux] Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Oncopole Claudius Regaud Service Hématologie - IUCT-Oncopole [CHU Toulouse] Institut de Recherche en Cancérologie de Montpellier Institut régional de Cancérologie de Montpellier Institut Curie [Paris] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Institut Gustave Roussy Institut Bergonié [Bordeaux] Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Oncopole Claudius Regaud Service Hématologie - IUCT-Oncopole [CHU Toulouse] Institut de Recherche en Cancérologie de Montpellier Institut régional de Cancérologie de Montpellier Institut Curie [Paris] Hôpital de la Timone [CHU - APHM] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Institut Gustave Roussy Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Institut Gustave Roussy Institut Bergonié [Bordeaux] Institut Bergonié [Bordeaux] Institut Gustave Roussy Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Institut Gustave Roussy
- Publié dans The Lancet Regional Health - Europe le 21/04/2021
Résumé : Background Liposarcomas (LPS) are among the most common sarcomas, but gather a diversity of rare to ultrarare molecular subtypes whose presentations and natural histories are partially characterized. The aim of the work was to describe the presentation and outcome of the different LPS histotypes from the NETSARC+ registry. Methods NETSARC+ (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB), funded by the French INCA since 2010 aiming to improve the quality of care of sarcoma patients. Patients' characteristics, treatment and outcomes are collected in a nationwide database. This work describes the outcome of all LPS confirmed by central review pathology review and integrated between 2010 and 2023 in the NETSARC+ database. Findings 11,132 liposarcomas are included in the database for an estimated incidence of 11.5/10 6 /y. Median age was 65 (Q1-Q3: 53-74, range 0-97 y), with 6529 males (58.7%), with 4220 (37.9%) dedifferentiated (DDLPS), 1838 (16.5%) well differentiated LPS (WDLPS) & 2424 (21.8%) atypical lipomatous tumours (ALT), 1371 (12.3%) myxoid LPS (MyxLPS), 450 (4.0%) pleomorphic LPS (PLPS), 177 (1.6%) high grade myxoid LPS (HGMLPS), 24 (0.2%) mixed type liposarcomas (MTLPS), 14 (0.1%) myxoid pleomorphic LPS (MPLPS) and 614 (5.5%) non classified LPS (NCLPS). Age, sex and sites differed across histotypes, but overall, all histotypes were represent in all age groups and sites. We report first on a difference in the sex ratio of liposarcoma in different age groups. Women were less frequently affected with liposarcomas after 50, in DDLPS, MyxLPS and HGMLPS. The median overall survival of DDLPS was 144 months, significantly worse than that of MyxLPS (HR: 0.26 [95% CI 0.21–0.33]), PLPS (HR: 0.76 [95% CI 0.59–0.98]), HGMLPS (HR: 0.30 [95% CI 0.18–0.50]), WDLPS (HR: 0.30 [95% CI 0.24–0.37]), unclassified LPS (HR: 0.53 [95% CI 0.37–0.75]). In addition to a lower incidence, women aged >50 had a better relapse free and overall survival than male, while this was not observed in the group aged 50 or under. In multivariate analyses, size and age were independent prognostic factors for the most common subgroups, but specific prognostic parameters were observed in each molecular subgroup. Female >50 was an independent favorable prognostic factor for the largest groups of DDLPS. Interpretation In this nationwide series of pathology-confirmed LPS, the clinical presentation, management and survival of histotypes are very different with age-related sex differences favoring women >50. DDLPS is the subtype with the worse prognosis
Fichiers liés : main_1.pdf
Source -
Long-term exposure of mice to sodium fluoride and to a mixture of endocrine disruptors causes tooth enamel and retina abnormalities associated with changes in hepatic metabolism
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Émilie PicardFatima Domenica Elisa de PalmaSophia LoiodiceVincent CarbonnierSeiki AchiedoNoor MimounDiluxe MutaleSophie DoublierSylvère DurandMélanie BourginFanny AprahamianPierre CordierLouise GutterKatia JedeonMarie-Christine NaudPhilippe NoirezJean-Marc RicortLotfi SlimaniGuido KroemerFrancine Behar-CohenMaria Chiara MaiuriSylvie Babajko
Long-term exposure of mice to sodium fluoride and to a mixture of endocrine disruptors causes tooth enamel and retina abnormalities associated with changes in hepatic metabolism
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Émilie PicardFatima Domenica Elisa de PalmaSophia LoiodiceVincent CarbonnierSeiki AchiedoNoor MimounDiluxe MutaleSophie DoublierSylvère DurandMélanie BourginFanny AprahamianPierre CordierLouise GutterKatia JedeonMarie-Christine NaudPhilippe NoirezJean-Marc RicortLotfi SlimaniGuido KroemerFrancine Behar-CohenMaria Chiara MaiuriSylvie Babajko
- Organismes : Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Santé orale Centre de Recherche des Cordeliers Métabolisme, cancer et immunité = Metabolism, Cancer & Immunity [CRC] Métabolisme, cancer et immunité = Metabolism, Cancer & Immunity [CRC] Métabolisme, cancer et immunité = Metabolism, Cancer & Immunity [CRC] École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique Centre de Recherche des Cordeliers Santé orale Centre de Recherche des Cordeliers Performance, Santé, Métrologie, Société - EA 7507 Santé orale Ecole Normale Supérieure Paris-Saclay Santé orale Centre de Recherche des Cordeliers Institut Gustave Roussy Cancer Research and Personalized Medicine - CARPEM [Paris] Centre de Recherche des Cordeliers Métabolisme, Cancer et Immunité Santé orale
- Publié dans Environment International le 30/10/2020
Résumé : Exposure to environmental pollutants may contribute to various health disorders, often manifesting after a prolonged period of latency. The identification of early markers is, therefore, of paramount importance.To achieve this objective, realistic models of environmental exposure were set up. Whereas most studies consider one substance or mixture with one target organ, here, in addition to the liver, two easily accessible sensitive organs, the eyes and teeth, were analyzed as good potential candidates to be original markers of environmental exposures. C57BL/6J mice were exposed to either sodium fluoride or a mixture of 15 endocrine-disrupting substances, or both, in their drinking water from the time of conception until 1 or 10 months after birth. The doses of these substances were chosen to be close to the tolerable daily intake.
All mice in test groups presented lower weight gain than controls with the most significant differences observed in females 30 days after birth. Alterations in the eye retina were detected as early as 1 month of age and considerably worsened by 10 months. Dental defects were observed in all test groups at the last time point. At that age, metabolic disruptions were identified through molecular metabolomic and RNAseq analyses, while histological analyses showed no significant defects in liver.
This study shows that chronic exposure to widespread toxicants resulted in hepatic metabolic disorders. However, the most evident histological and clinical signs were observed in eyes and teeth. These easily accessible stigmata may be used as early markers of low-dose exposure to environmental toxicants.
Fichiers liés : Picard, de Palma et al main_post print.pdf
Source
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Antoine GavoilleFabien RollotRomain CaseyGuillaume MatheyEmmanuelle Le PageJonathan CironJérôme de SèzeAurélie RuetElisabeth MaillartPierre LabaugeHélène ZephirArnaud KwiatkowskiCaroline PapeixGilles DeferChristine Lebrun-FrenayThibault MoreauDavid-Axel LaplaudEric BergerAnne-Laure DubessyPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierAbdullatif Al-KhedrOlivier CasezBertrand BourreAbir WahabLaurent MagySolène MoulinJean-Philippe CamdessanchéInès DoghriMariana Sarov-RiviereKarolina HankiewiczCorinne PottierAmélie dos SantosChantal NifleFabien SubtilSandra VukusicFrançois CottonPascal DouekF. GuilleminAlexandre PachotJavier OlaizClaire Rigaud-BullyRomain MarignierGuillaume MatheyAnne KerbratDamien BiottiJean-Christophe OualletNicolas CollonguesOlivier OutteryckXavier MoissetNathalie DeracheMikaël CohenAgnès FromontSandrine WiertlewskyMatthieu BereauBertrand AudoinClaire GiannesiniCaroline BensaGiovanni CastelnovoOmbeline FagniezBenjamin HebantMathieu VaillantSéverine JeaninAlain CréangeJean-Michel VallatPhilippe ConversStéphane BeltranCéline LabeyrieCarole HenryMarie CamuzeauxMaryline DelattreLaura TrottaCatherine GirodAmandine Ostermann-ZieglerDamien Le PortNoellie FreitasCarole BertheKaty-Kim LatasteKarima ZehrouniFrédéric PinnaJulie PetitSadou Safa DialloKarine DroulonCéline CallierAlexia ProtinMelinda MoyonChrystelle CappeEmilie DumontHanane AgherbiMarie BlanchereMarie-Pierre RanjevaAmandine da VeigaMaty Diop KaneChristine VimontMarjory CayolSafiyatou BaldeDaisy RousseauKarine FerraudGéraldine MeunierElise VarnierEdwige LescieuxHalima BourenaneStéphanie CossecÉmilie RaboisLynda BenammarAnaïs Beulaygue
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis
- Type de publi. : Article dans une revue
- Date de publi. : 01/10/2025
- Auteurs : Antoine GavoilleFabien RollotRomain CaseyGuillaume MatheyEmmanuelle Le PageJonathan CironJérôme de SèzeAurélie RuetElisabeth MaillartPierre LabaugeHélène ZephirArnaud KwiatkowskiCaroline PapeixGilles DeferChristine Lebrun-FrenayThibault MoreauDavid-Axel LaplaudEric BergerAnne-Laure DubessyPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierAbdullatif Al-KhedrOlivier CasezBertrand BourreAbir WahabLaurent MagySolène MoulinJean-Philippe CamdessanchéInès DoghriMariana Sarov-RiviereKarolina HankiewiczCorinne PottierAmélie dos SantosChantal NifleFabien SubtilSandra VukusicFrançois CottonPascal DouekF. GuilleminAlexandre PachotJavier OlaizClaire Rigaud-BullyRomain MarignierGuillaume MatheyAnne KerbratDamien BiottiJean-Christophe OualletNicolas CollonguesOlivier OutteryckXavier MoissetNathalie DeracheMikaël CohenAgnès FromontSandrine WiertlewskyMatthieu BereauBertrand AudoinClaire GiannesiniCaroline BensaGiovanni CastelnovoOmbeline FagniezBenjamin HebantMathieu VaillantSéverine JeaninAlain CréangeJean-Michel VallatPhilippe ConversStéphane BeltranCéline LabeyrieCarole HenryMarie CamuzeauxMaryline DelattreLaura TrottaCatherine GirodAmandine Ostermann-ZieglerDamien Le PortNoellie FreitasCarole BertheKaty-Kim LatasteKarima ZehrouniFrédéric PinnaJulie PetitSadou Safa DialloKarine DroulonCéline CallierAlexia ProtinMelinda MoyonChrystelle CappeEmilie DumontHanane AgherbiMarie BlanchereMarie-Pierre RanjevaAmandine da VeigaMaty Diop KaneChristine VimontMarjory CayolSafiyatou BaldeDaisy RousseauKarine FerraudGéraldine MeunierElise VarnierEdwige LescieuxHalima BourenaneStéphanie CossecÉmilie RaboisLynda BenammarAnaïs Beulaygue
- Organismes : Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Hospices Civils de Lyon Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Hospices Civils de Lyon Service de neurologie [CHRU Nancy] INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Centre d'investigation clinique - Epidémiologie clinique [Nancy] Service de Neurologie [CHU Rennes] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Toulouse Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] CIC Strasbourg Service de Neurologie [Strasbourg] Service de neurologie [Bordeaux] Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Saint Vincent de Paul [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Université Paris Cité Service de Neurologie [CHU Caen] Normandie Université UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Service de Neurologie [CHU Nice] Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Service de Neurologie [CHRU Besançon] CHU Pitié-Salpêtrière [AP-HP] Service Neurologie [CHU Clermont-Ferrand] Neuro-Dol Service de Neurologie [CHU Nimes] Institut de Génomique Fonctionnelle Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Service de neurologie [Amiens] Pôle Psychiatrie et Neurologie [Grenoble] Translational Research in Autoimmunity and Inflammation Group Service de neurologie [Rouen] Hôpital Henri Mondor Service de Neurologie [CHU Limoges] Service de neurologie [Reims] Service de Neurologie [CHU de Saint-Étienne] Hôpital Bretonneau Service de neurologie [Le Kremlin Bicêtre] Centre Hospitalier de Saint-Denis [Ile-de-France] hôpital NOVO Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CIC Poitiers – Centre d'investigation clinique de Poitiers Centre Hospitalier de Versailles André Mignot Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS
- Publié dans JAMA neurology le 24/10/2020
Résumé : Importance: In women with multiple sclerosis (MS), disease-modifying therapy (DMT) management during pregnancy might impact relapse risk. Objective: To estimate the effect of DMT management during pregnancy on MS relapse rate and compare different therapeutic strategies. Design, setting, and participants: This was a multicenter retrospective cohort study using data from January 1990 to December 2023. Data were extracted in December 2023 from the French MS registry. Among 52 955 women in the registry, we included pregnancies identified through childbirths in patients with relapsing-onset MS who were monitored for at least 18 months before delivery and 9 months after. Pregnancies occurring less than 18 months apart or with missing month of birth were excluded. Exposures: Mediation analysis was used to estimate the total, direct, and indirect (mediated by DMT management) effects of pregnancy. Different therapeutic strategies were compared: DMT interruption, switching to or maintaining interferon β or glatiramer acetate, switching to or maintaining natalizumab until the third trimester, and switching to or maintaining intravenous anti-CD20 and interrupting it 3 months before conception. Main outcomes and measures: The primary outcome was the annualized relapse rate (ARR) during the preconception, gestation, and postpartum periods. Within a causal inference framework, counterfactual ARRs were estimated using longitudinal g-computation, combining a random forest algorithm for predicting DMTs, and a mixed-effects Poisson model for relapses. Results: We included 6341 pregnancies occurring in 4998 women (mean [SD] age at conception, 31.5 [4.5] years). DMT management during pregnancy significantly increased ARR during gestation (causal rate ratio [cRR], 1.13; 95% CI, 1.06-1.22) and postpartum (cRR, 1.08; 95% CI, 1.01-1.16) periods. This led to a deleterious total effect of pregnancy on ARR, particularly in women receiving natalizumab before pregnancy with prolonged interruption (ie, interruption before the second trimester or resumption more than 3 months after delivery; cRR, 2.18; 95% CI, 1.76-2.69), and in women receiving fingolimod (cRR, 2.15; 95% CI, 1.60-2.93). Compared to DMT interruption, anti-CD20 strategy was the most effective (cRR, 0.38; 95% CI, 0.25-0.52), followed by the natalizumab strategy with short interruption (cRR, 0.80; 95% CI, 0.71-0.90), whereas interferon β (cRR, 0.93; 95% CI, 0.86-0.99) and glatiramer acetate strategies (cRR, 0.91; 95% CI, 0.84-0.99) were less effective. Conclusion: In this study, DMT management during pregnancy significantly increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. The strategy based on the use of anti-CD20 before pregnancy was the most effective to mitigate this risk.
Fichiers liés : Gavoille - 2025 - Therapeutic Management during Pregnancy on Relapse Risk in.pdf
Source